Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FOLR1 expression
i
Other names:
FOLR1, Folate Receptor Alpha, Ovarian Tumor-Associated Antigen MOv18, Adult Folate-Binding Protein, Folate Receptor 1 (Adult), Folate Receptor, Adult, Folate Receptor 1, KB Cells FBP, FR-Alpha, FOLR, FBP, Folate Binding Protein, FRalpha
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2348
Related biomarkers:
Expression
‹
›
Related tests:
VENTANA FOLR1 RxDx Assay (5)
VENTANA FOLR1 RxDx Assay (5)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Fallopian Tube Cancer
FOLR1 expression
Fallopian Tube Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Peritoneal Cancer
FOLR1 expression
Peritoneal Cancer
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
bevacizumab + mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Peritoneal Cancer
FOLR1 expression
Peritoneal Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Fallopian Tube Cancer
FOLR1 expression
Fallopian Tube Cancer
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
mirvetuximab soravtansine-gynx
Sensitive: A2 - Guideline
mirvetuximab soravtansine-gynx
Sensitive
:
A2
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
STRO-002
Sensitive: C2 – Inclusion Criteria
STRO-002
Sensitive
:
C2
STRO-002
Sensitive: C2 – Inclusion Criteria
STRO-002
Sensitive
:
C2
FOLR1 expression
Endometrial Cancer
FOLR1 expression
Endometrial Cancer
rinatabart sesutecan
Sensitive: C2 – Inclusion Criteria
rinatabart sesutecan
Sensitive
:
C2
rinatabart sesutecan
Sensitive: C2 – Inclusion Criteria
rinatabart sesutecan
Sensitive
:
C2
FOLR1 expression
Endometrial Cancer
FOLR1 expression
Endometrial Cancer
mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
mirvetuximab soravtansine-gynx
Sensitive
:
C3
mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
mirvetuximab soravtansine-gynx
Sensitive
:
C3
FOLR1 expression
Solid Tumor
FOLR1 expression
Solid Tumor
MORAb-202
Sensitive: C3 – Early Trials
MORAb-202
Sensitive
:
C3
MORAb-202
Sensitive: C3 – Early Trials
MORAb-202
Sensitive
:
C3
FOLR1 expression
Ovarian Cancer
FOLR1 expression
Ovarian Cancer
rucaparib + mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
rucaparib + mirvetuximab soravtansine-gynx
Sensitive
:
C3
rucaparib + mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
rucaparib + mirvetuximab soravtansine-gynx
Sensitive
:
C3
FOLR1 expression
Endometrial Cancer
FOLR1 expression
Endometrial Cancer
rucaparib + mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
rucaparib + mirvetuximab soravtansine-gynx
Sensitive
:
C3
rucaparib + mirvetuximab soravtansine-gynx
Sensitive: C3 – Early Trials
rucaparib + mirvetuximab soravtansine-gynx
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.